Costamagna Andrea, Pasquino Chiara, Lamorte Sara, Navarro-Tableros Victor, Delsedime Luisa, Fanelli Vito, Camussi Giovanni, Del Sorbo Lorenzo
Department of Surgical Sciences, University of Turin, Turin, Italy.
Molecular Biotechnology Center, University of Turin, Turin, Italy.
Intensive Care Med Exp. 2024 Dec 3;12(1):111. doi: 10.1186/s40635-024-00701-z.
Sepsis is a condition with high mortality and morbidity, characterized by deregulation of the immune response against the pathogen. Current treatment strategies rely mainly on antibiotics and supportive care. However, there is growing interest in exploring cell-based therapies as complementary approaches. Human liver stem cells (HLSCs) are pluripotent cells of mesenchymal origin, showing some advantages compared to mesenchymal stem cells in terms of immunomodulatory properties. HSLC-derived extracellular vesicles (EVs) exhibited a superior efficacy profile compared to cells due to their potential to get through biological barriers and possibly to avoid tumorigenicity and showed to be effective in vivo and ex vivo models of liver and kidney disease. The potential of HLSCs and their EVs in recovering damage to distal organs due to sepsis other than the kidney remains unknown. This study aimed to investigate the therapeutic potential of the intravenous administration of HSLCs or HSLCs-derived EVs in a murine model of sepsis.
Sepsis was induced by caecal ligation and puncture (CLP) on C57/BL6 mice. After CLP, mice were assigned to receive either normal saline, HLSCs or their EVs and compared to a sham group which underwent only laparotomy. Survival, persistence of bacteraemia, lung function evaluation, histology and bone marrow analysis were performed. Administration of HLSCs or HLSC-EVs resulted in improved bacterial clearance and lung function in terms of lung elastance and oedema. Naïve murine hematopoietic progenitors in bone marrow were enhanced after treatment as well. Administration of HLSCs and HLSC-EVs after CLP to significantly improved survival.
Treatment with HLSCs or HLSC-derived EVs was effective in improving acute lung injury, dysmyelopoiesis and ultimately survival in this experimental murine model of lethal sepsis.
脓毒症是一种死亡率和发病率都很高的病症,其特征是针对病原体的免疫反应失调。当前的治疗策略主要依赖抗生素和支持性护理。然而,人们越来越有兴趣探索基于细胞的疗法作为补充方法。人肝干细胞(HLSCs)是间充质来源的多能细胞,在免疫调节特性方面比间充质干细胞具有一些优势。与细胞相比,HLSC衍生的细胞外囊泡(EVs)由于其穿透生物屏障的潜力以及可能避免致瘤性,表现出更高的疗效,并且在肝脏和肾脏疾病的体内和体外模型中均显示有效。HLSCs及其EVs在恢复除肾脏外因脓毒症导致的远端器官损伤方面的潜力尚不清楚。本研究旨在调查静脉注射HLSCs或HLSCs衍生的EVs在脓毒症小鼠模型中的治疗潜力。
通过对C57/BL6小鼠进行盲肠结扎和穿刺(CLP)诱导脓毒症。CLP后,将小鼠分为接受生理盐水、HLSCs或其EVs的组,并与仅接受剖腹手术的假手术组进行比较。进行了生存、菌血症持续时间、肺功能评估、组织学和骨髓分析。HLSCs或HLSC-EVs的给药在肺弹性和水肿方面改善了细菌清除和肺功能。治疗后骨髓中未成熟的小鼠造血祖细胞也得到了增强。CLP后给予HLSCs和HLSC-EVs显著提高了生存率。
在这个致命性脓毒症的实验小鼠模型中,用HLSCs或HLSC衍生的EVs进行治疗可有效改善急性肺损伤、骨髓生成异常,并最终提高生存率。